Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionQuantbot Technologies LP
Latest Disclosed Ownership3,288 shares
Latest Disclosed Value $ 212,503
Quantbot Technologies LP reports 22.67% decrease in ownership of HALO / Halozyme Therapeutics, Inc.

On May 13, 2026 - Quantbot Technologies LP filed a 13F-HR form disclosing ownership of 3,288 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $212,503 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 4,252 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -22.67% during the quarter. The current value of the position is $229,568 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,288 -964 -22.67 213 -25.87 0.0087
2026-02-10 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 4,252 -4,121 -49.22 286 -53.42 0.0095
2025-11-12 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 8,373 -7,499 -47.25 614 -25.58 0.0167
2025-08-13 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 15,872 6,981 78.52 826 45.50 0.0212
2025-05-13 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 8,891 1,230 16.06 567 54.92 0.0181
2025-02-11 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 7,661 5,047 193.08 366 145.64 0.0134
2024-11-13 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,614 2,614 150 0.0059
2023-05-12 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -6,683 -100.00 0 -100.00
2023-02-13 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,683 6,683 380 0.0273
2022-11-07 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 0 -6,500 -100.00 0 -100.00
2022-08-09 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 6,500 6,500 286 0.0263
2022-02-11 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -3,660 -100.00 0 -100.00
2021-11-09 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,660 -1,890 -34.05 148 -41.27 0.0108
2021-08-12 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 5,550 -1,266 -18.57 252 -11.27 0.0198
2021-05-14 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,816 207 3.13 284 0.71 0.0270
2021-02-12 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,609 2,804 73.69 282 184.85 0.0293
2020-11-16 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,805 2,659 232.02 99 230.00 0.0114
2020-08-13 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,146 864 306.38 30 500.00 0.0040
2020-05-13 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 282 -2,279 -88.99 5 -88.89 0.0033
2020-02-10 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,561 1,561 156.10 45 200.00 0.0045
2019-11-12 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,000 -600 -37.50 15 -44.44 0.0015
2019-08-13 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,600 1,600 27 0.0027
2019-02-13 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -3,510 -100.00 0 -100.00
2018-11-13 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,510 3,510 63 0.0044
2016-04-28 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 0 0 0.0000
2016-01-22 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -2,200 -100.00 0 -100.00
2015-10-22 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,200 2,200 29 0.0051
2015-07-27 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 0 -6,124 -100.00 0 -100.00
2015-04-24 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 6,124 6,124 87 0.0215
2014-10-15 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 0 -3,032 -100.00 0 -100.00
2014-07-08 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,032 3,032 29 0.0046
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.